Trial Profile
Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sulindac
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics
- 06 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 11 Apr 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 31 May 2013 Status changed from active, no longer recruiting to completed.